Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04320823 · ClinicalTrials.gov registry record · NA

IMPACT (Improving Plasma Collection) Clinical Trial

A NA study of Apheresis Related Hypotension, sponsored by Haemonetics Corporation.

Completed
Registry status
NA
Development phase
3,443
Enrollment target
3
Study locations

NCT04320823 is a NA study of Apheresis Related Hypotension that has completed, run by Haemonetics Corporation. The registered enrollment target is 3,443 participants. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04320823, a NA study of Apheresis Related Hypotension, has completed, sponsored by Haemonetics Corporation.

COMPLETED
Registry status
NA
Development phase
3,443 participants
Enrollment target
3
Study locations

Study Summary

Prospective, multi-center, randomized, controlled clinical trial to study the safety and effectiveness of a novel plasma collection system software.

Interventions

  • DEVICE Updated Plasma Collection Feature
  • DEVICE Current Plasma Collection Approach

Study Locations (3)

Kansas

  • Octapharma Plasma - Wichita

North Carolina

  • Octapharma Plasma - Charlotte

Washington

  • Octapharma Plasma - Spokane

Trial Details

FieldValue
Enrollment Target 3,443 participants
Start Date 2020-01-06
Est. Completion 2020-04-27
Phase NA

Sponsor

Haemonetics Corporation

11 total trials

What the Registry Record Tells You About NCT04320823

The ClinicalTrials.gov registry entry for NCT04320823 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,443 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Haemonetics Corporation, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Apheresis Related Hypotension appearing as the primary indexed condition, and to 2 interventions - of which Updated Plasma Collection Feature is the first listed.

NCT04320823 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kansas, North Carolina, Washington.

Frequently Asked Questions

What is clinical trial NCT04320823 about?

NCT04320823 is a clinical study titled "IMPACT (Improving Plasma Collection) Clinical Trial". Prospective, multi-center, randomized, controlled clinical trial to study the safety and effectiveness of a novel plasma collection system software.

What is the current status of trial NCT04320823?

This trial is currently completed. It is a NA study. The enrollment target is 3,443 participants. The study started on 2020-01-06. Estimated completion is 2020-04-27.

What conditions does trial NCT04320823 study?

This clinical trial studies the following conditions: Apheresis Related Hypotension.

What interventions are being tested in trial NCT04320823?

The interventions under investigation include: Updated Plasma Collection Feature (DEVICE), Current Plasma Collection Approach (DEVICE).

Who is sponsoring clinical trial NCT04320823?

This trial is sponsored by Haemonetics Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04320823 being conducted?

This trial has 3 study locations across Kansas, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.